UNCY - The Unmet Need For Innovative And Effective Treatments For Kidney Disease: Acute Kidney Injury
(NewsDirect)
By Julian Richard, Benzinga
UnicyciveTherapeutics Inc (NASDAQ: UNCY) is a biopharmaceutical companyspearheading efforts to develop effective, safe, and novel treatmentsfor kidney disease to improve patient and caregiver quality of lifedue to kidney failure. Its candidate UNI-494 is currently indevelopment for treating acute kidney injury (AKI).
Acute kidney injury(AKI) is a serious, life-threatening condition caused by an acute lossof kidney function. There are several causes of AKI, including heartfailure and liver disease, blockage to the kidney and reduced bloodflow, and drugs or toxic substances. Recentresearch has highlighted the role that mitochondrialdysfunction plays in AKI pathogenesis. Mitochondria are organelles (specialized structures within cells that perform specific functions)that produce energy for cell functions and regulate many otherbiological processes, such as cell death. When mitochondria become dysfunctional due to illness or trauma, it can lead to various diseases, includingAKI.
Treatmentfor AKI currently focuses on supportivecare measures such as administering fluids and electrolytes tostabilize the patient’s blood pressure and dialysis treatment toremove waste from the body. While these treatments are effective intreating the symptoms of AKI, they fail to address the underlyingcause of this medical condition and thus do not affect the progressionof the disease. Symptoms of AKI include decreased frequency of urination and swelling in thelegs and may lead to chronic kidney disease if not treated.Unfortunately, treatment options for mitochondrial dysfunction arelimited. While several promising treatments can restore mitochondrialfunction, such as using antioxidants and other compounds to reduceoxidative stress, these treatments have yet to be successfullyimplemented on a large scale. This unmet medical need has left manypatients with few treatment options.
UNI-494 is a promising compound seeking to addressthis unmet clinical need. It is a patented pro-drug (a biologicallyinactive compound that can be metabolized in the body to produce anactive drug) of nicorandil ,which has been shown in preclinical models to improve mitochondrialfunction. Datafor UNI-494 from three pre-clinical studies will be presentedat the National Kidney Foundation’s (NFK) upcoming Spring ClinicalMeetings in April 2023.
“We are delighted to be presenting this bolus of data insupport of UNI-494 as a potential treatment advance for acute kidneyinjury” said ShalabhGupta, M.D ., Chief Executive Officer of UnicyciveTherapeutics.
Visit https://unicycive.com formore information on the company and its product candidates.
This article wasoriginally published on Benzinga here .
UnicyciveTherapeutics is a biotechnology company developing novel treatmentsfor kidney diseases. Unicycive’s lead drug, Renazorb, is a novelphosphate binding agent being developed for the treatment ofhyperphosphatemia. UNI-494 is a patent-protected new chemical entityin late preclinical development for the treatment of acute kidneyinjury.
This post contains sponsored advertising content.This content is for informational purposes only and is not intended tobe investing advice.
Contact Details
AnneMarie Fields - Stern Investor Relations
+1 212-362-1200
CompanyWebsite
Copyright (c) 2023 TheNewswire - All rights reserved.